ALLARITY Sponsors $100M SPAC IPO Filed With the SEC
The Phase 2 cancer drug developer is sponsoring Allarity Acquisition Corp., which filed for a $100 million unit IPO on Nasdaq under the symbol ALLNU.
Allarity Therapeutics (ALLR) said a newly formed special purpose acquisition company it sponsors, Allarity Acquisition Corp., has publicly filed a Form S-1 registration statement with the SEC for a proposed initial public offering of units. The base offering size is expected to be $100 million, rising to $115 million if underwriters exercise their over-allotment option in full.
